Report Highlights

Role of the United States in the Global TB Vaccine Supply Chain

The United States sits at the demand and innovation end of the tuberculosis vaccine supply chain rather than at production. Bulk BCG for global programs is manufactured by Statens Serum Institut in Denmark and Serum Institute of India, and US-licensed supply has historically depended on those foreign sources. Domestic capacity is confined to fill-finish, packaging and clinical-lot work, so the country imports nearly all vaccine active ingredient.

Value capture concentrates in clinical development and regulatory approval. The United States contributes regulatory leadership and trial funding to M72/AS01E, the GSK and Gates Medical Research Institute candidate that entered Phase 3 in 2024 with roughly 20,000 participants. On the treatment side, finished anti-TB drugs depend on active pharmaceutical ingredients sourced predominantly from India and China, leaving domestic regimens exposed to a two-country concentration.

Growth Drivers for TB Vaccines and Treatment in the United States

Case growth is the primary demand driver. The CDC recorded 10,347 US tuberculosis cases in 2023, the highest annual count since 2011, with foreign-born residents accounting for the majority. Rising caseloads in California, Texas and New York lift demand for diagnostics, first-line drugs and high-risk pediatric vaccination, pulling API imports from India and China upward through 2026.

Pipeline advancement and domestic manufacturing policy form the second driver. Phase 3 progress on M72/AS01E and on MTBVAC from Biofabri positions licensure filings for the early 2030s, which triggers stockpile procurement and cold-chain logistics planning. Federal onshoring incentives, including FDA's 2025 PreCheck program for new US manufacturing facilities, encourage fill-finish investment and reduce reliance on imported bulk material.

Supply Chain Risks and Trade Barriers

Active ingredient concentration is the most acute exposure. Finished isoniazid, rifampin and bedaquiline generics draw API from a narrow group of Indian and Chinese manufacturers, and any export restriction or port disruption transmits directly into US shortages. Section 232 pharmaceutical tariffs opened in 2025 add cost uncertainty to every imported active ingredient that enters the market without a trade exemption.

Cold-chain and diagnostics bottlenecks compound the risk. Live attenuated BCG requires storage at 2 to 8 degrees Celsius through distribution to clinics, and rural and correctional facilities have limited refrigerated handling. Interferon-gamma release assay reagents come from a concentrated supplier group, so a single-supplier disruption would stall the screening on which vaccine eligibility depends.

Trade and Investment Opportunities in the United States

Onshore fill-finish and API capacity represent the clearest import-substitution play. Contract manufacturers that add sterile fill lines for BCG or recombinant subunit vaccines capture a market where the US currently imports nearly all bulk material. Indian generic producers that already hold FDA-approved sites can dual-source anti-TB intermediates through US-based contract manufacturers.

Inbound FDI and logistics hubs offer secondary opportunities. Foreign diagnostics makers can establish US reagent production near national distribution nodes, and Memphis and Louisville, both major express-air hubs, offer temperature-controlled sites close to population centres. Investors should target cold-chain third-party logistics capacity in Texas and California, where case concentration justifies dedicated refrigerated inventory.

Market at a Glance

Leading Market Participants

• GlaxoSmithKline
• Gates Medical Research Institute
• Serum Institute of India
• Statens Serum Institut
• Biofabri
• Johnson & Johnson
• Otsuka Pharmaceutical
• Merck & Co.
• Qiagen
• Lupin

Regulatory and Trade Policy Environment

Vaccine approval runs through the FDA's Center for Biologics Evaluation and Research under a biologics license application, while ACIP recommendations determine insurance coverage and Vaccines for Children eligibility. TB drugs follow standard NDA and ANDA pathways, and the CDC's Division of Tuberculosis Elimination sets treatment protocols that shape reimbursement under Medicare Part D and Medicaid. Manufacturers must register facilities with the FDA and comply with current good manufacturing practice.

Trade policy is shaped by broad instruments rather than TB-specific agreements. The US has no bilateral agreement dedicated to tuberculosis products, so imports of finished vaccines and APIs move under WTO tariff schedules, most-favoured-nation treatment and the Section 232 pharmaceutical investigation. Foreign acquisitions of US production assets face CFIUS review, while USMCA governs pharmaceutical inputs traded with Mexico and Canada.

U.S. TB Vaccine Supply Chain Outlook to 2032

The supply chain position will shift from import dependency toward domestic fill-finish and diagnostic reagent capacity by 2032. Phase 3 readouts for M72/AS01E in the late 2020s will move procurement toward a single recombinant subunit product, shifting cold-chain demand toward standard refrigerated distribution and reducing live-vaccine handling risk.

Technology changes will alter comparative advantage. Point-of-care TB tests and sequencing platforms from Illumina reduce reliance on centralized laboratories and redirect reagent flows toward distributed testing sites. Vaccine value chains built on adjuvant systems such as AS01E favour contract manufacturers with aseptic capacity, shifting trade from bulk BCG shipments toward finished-dose imports.